Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis - PubMed
4 hours ago
- #personalized therapy
- #ulcerative colitis
- #infliximab
- Infliximab is used as rescue therapy for steroid-refractory acute severe ulcerative colitis (ASUC).
- A model was developed to predict colectomy risk within 90 days of infliximab initiation.
- The study included 72 patients with ASUC from seven medical centers, with 11 colectomies within 90 days.
- The strongest predictor of colectomy was the clearance-normalized exposure between weeks 2 and 4 (AUCw2-4/CL).
- Patients with a log-transformed AUCw2-4/CL ratio < 5.79 were classified as high risk for colectomy.
- An interactive tool was developed to enable personalized infliximab rescue therapy based on the model.